ABEONA THERAPEUT. DL-01 - Asset Resilience Ratio
ABEONA THERAPEUT. DL-01 (PCJ) has an Asset Resilience Ratio of 51.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PCJ total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ABEONA THERAPEUT. DL-01's Asset Resilience Ratio has changed over time. See net assets of ABEONA THERAPEUT. DL-01 for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ABEONA THERAPEUT. DL-01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PCJ market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €112.97 Million | 51.45% |
| Total Liquid Assets | €112.97 Million | 51.45% |
Asset Resilience Insights
- Very High Liquidity: ABEONA THERAPEUT. DL-01 maintains exceptional liquid asset reserves at 51.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABEONA THERAPEUT. DL-01 Industry Peers by Asset Resilience Ratio
Compare ABEONA THERAPEUT. DL-01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ABEONA THERAPEUT. DL-01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.45% | €112.97 Million ≈ $132.07 Million |
€219.57 Million ≈ $256.70 Million |
-16.82pp |
| 2024-12-31 | 68.27% | €74.36 Million ≈ $86.94 Million |
€108.93 Million ≈ $127.35 Million |
+9.28pp |
| 2023-12-31 | 58.99% | €37.75 Million ≈ $44.14 Million |
€64.00 Million ≈ $74.83 Million |
-0.08pp |
| 2022-12-31 | 59.07% | €37.93 Million ≈ $44.35 Million |
€64.21 Million ≈ $75.07 Million |
+43.89pp |
| 2021-12-31 | 15.19% | €12.09 Million ≈ $14.13 Million |
€79.59 Million ≈ $93.04 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more